United Therapeutics Corporation (UTHR)

Current ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Total current assets	US$ in thousands	3,873,900	4,000,400	3,619,500	3,248,700	3,551,000	3,458,900	3,213,400	3,193,000	3,380,300	3,056,400	2,684,300	2,586,600	2,323,600	2,385,900	2,317,900	2,014,300	2,167,200	1,868,200	1,894,400	1,846,300
Total current liabilities	US$ in thousands	738,100	873,400	832,300	860,600	804,400	744,100	370,300	324,600	343,200	315,900	331,500	292,600	305,400	320,000	311,400	302,400	323,300	258,900	255,000	207,300
Current ratio		5.25	4.58	4.35	3.77	4.41	4.65	8.68	9.84	9.85	9.68	8.10	8.84	7.61	7.46	7.44	6.66	6.70	7.22	7.43	8.91

December 31, 2024 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $3,873,900K ÷ $738,100K
= 5.25

The current ratio of United Therapeutics Corporation has shown fluctuating trends over the periods mentioned in the data. From March 31, 2020, to March 31, 2022, the current ratio consistently increased from 8.91 to 8.84, indicating a strong ability to cover short-term obligations with current assets. However, from March 31, 2022, to December 31, 2024, the current ratio declined gradually from 8.84 to 5.25, suggesting a potential decrease in liquidity and the company's ability to meet its short-term liabilities. Notably, the ratio dropped significantly between June 30, 2023, and March 31, 2024, indicating a notable liquidity strain during that period. Overall, while the current ratio remained above 1 (the threshold indicating a company's ability to cover its short-term liabilities), the downward trend towards the end of the provided data may warrant further investigation into United Therapeutics Corporation's liquidity management.